WntResearch carries out a rights issue of units of approximately SEK 56 million
The Board of Directors of Wntresearch AB ("WntResearch" or the “Company") has today, subject to subsequent approval by the extraordinary general meeting in the Company on 22 December 2023, resolved to carry out a rights issue of units, consisting of shares and warrants, with preferential rights for the Company’s existing shareholders (the "Rights Issue"). The Rights Issue is mainly intended to finance and complete the Company’s ongoing Phase 2 study NeoFox as well as continued clinical and regulatory development and intensified business development. In connection with the Rights Issue, the